Lanthionine synthetase C-like protein 2 (LanCL2) is a novel regulator of Akt

Molecular Biology of the Cell

Volumn 25, Issue 24, 2014, Pages 3954-3961

  Zeng, Min ^a   Van Der Donk, Wilfred A ^b   Chen, Jie ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE; LANTHIONINE; LANTHIONINE SYNTHETASE C LIKE 2 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; UNCLASSIFIED DRUG; ALANINE; LANCL2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MULTIPROTEIN COMPLEX; NUCLEAR PROTEIN; PROTEIN BINDING; SULFIDE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

APOPTOSIS; ARTICLE; CELL SURVIVAL; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ANALOGS AND DERIVATIVES; FLUORESCENCE MICROSCOPY; GENETICS; HEK293 CELL LINE; HEPG2 CELL LINE; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE; TRANSFORMED CELL LINE; WESTERN BLOTTING;

ALANINE; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; CELL SURVIVAL; HEK293 CELLS; HEP G2 CELLS; HUMANS; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; MULTIPROTEIN COMPLEXES; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SULFIDES; TOR SERINE-THREONINE KINASES;

EID: 84913529605     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E14-01-0004     Document Type: Article

References (36)

1. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol 7, 261-269.
2. Anai M, Shojima N, Katagiri H, Ogihara T, Sakoda H, Onishi Y, Ono H, Fujishiro M, Fukushima Y, Horike N, et al. (2005). A novel protein kinase B (PKB)/AKT-binding protein enhances PKB kinase activity and regulates DNA synthesis. J Biol Chem 280, 18525-18535.
3. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA (1997). Role of translocation in the activation and function of protein kinase B. J Biol Chem 272, 31515-31524.
4. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR (2005). Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94, 29-86.
5. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241.
6. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME (1997). Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275, 661-665.
7. Duronio V (2008). The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 415, 333-344.
8. Erbay E, Park IH, Nuzzi PD, Schoenherr CJ, Chen J (2003). IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients. J Cell Biol 163, 931-936.
9. Franke TF (2008). Intracellular signaling by Akt: bound to be specific. Sci Signal 1, pe29.
10. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN (1995). The protein kinase encoded by the Akt protooncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81, 727-736.
11. Gao T, Furnari F, Newton AC (2005). PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18, 13-24.
12. Garcia-Martinez J M, Alessi DR (2008). mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416, 375-385.
13. Gyorffy B, Serra V, Jurchott K, Abdul-Ghani R, Garber M, Stein U, Petersen I, Lage H, Dietel M, Schafer R (2005). Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 24, 7542-7551.
14. Ikenoue T, Hong S, Inoki K (2009). Monitoring mammalian target of rapamycin (mTOR) activity. Methods Enzymol 452, 165-180.
15. Knerr PJ, van der Donk WA (2012). Discovery, biosynthesis, and engineering of lantipeptides. Annu Rev Biochem 81, 479-505.
16. Landlinger C, Salzer U, Prohaska R (2006). Myristoylation of human LanClike protein 2 (LANCL2) is essential for the interaction with the plasma membrane and the increase in cellular sensitivity to adriamycin. Biochim Biophys Acta 1758, 1759-1767.
17. Lawlor MA, Alessi DR (2001). PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114, 2903-2910.
18. Li B, Yu JP, Brunzelle JS, Moll GN, van der Donk WA, Nair SK (2006). Structure and mechanism of the lantibiotic cyclase involved in nisin biosynthesis. Science 311, 1464-1467.
19. Magnone M, Sturla L, Jacchetti E, Scarfi S, Bruzzone S, Usai C, Guida L, Salis A, Damonte G, De Flora A, et al. (2012). Autocrine abscisic acid plays a key role in quartz-induced macrophage activation. FASEB J 26, 1261-1271.
20. Mitsuuchi Y, Johnson SW, Sonoda G, Tanno S, Golemis EA, Testa JR (1999). Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. Oncogene 18, 4891-4898.
21. Murray JT, Campbell DG, Morrice N, Auld GC, Shpiro N, Marquez R, Peggie M, Bain J, Bloomberg GB, Grahammer F, et al. (2004). Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J 384, 477-488.
22. Myers MG Jr., Backer JM, Sun XJ, Shoelson S, Hu P, Schlessinger J, Yoakim M, Schaffhausen B, White MF (1992). IRS-1 activates phosphatidylinositol 32-kinase by associating with src homology 2 domains of p85. Proc Natl Acad Sci USA 89, 10350-10354.
23. Nakamura A, Naito M, Tsuruo T, Fujita N (2008). Freud-1/Aki1, a novel PDK1- interacting protein, functions as a scaffold to activate the PDK1/Akt pathway in epidermal growth factor signaling. Mol Cell Biol 28, 5996-6009.
24. Namikawa K, Honma M, Abe K, Takeda M, Mansur K, Obata T, Miwa A, Okado H, Kiyama H (2000). Akt/protein kinase B prevents injury-induced motoneuron death and accelerates axonal regeneration. J Neurosci 20, 2875-2886.
25. Park S, James CD (2003). Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism. Cancer Res 63, 723-727.
26. Park SH, Zarrinpar A, Lim WA (2003). Rewiring MAP kinase pathways using alternative scaffold assembly mechanisms. Science 299, 1061-1064.
27. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR (1999). Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96, 2110-2115.
28. Ries V, Henchcliffe C, Kareva T, Rzhetskaya M, Bland R, During MJ, Kholodilov N, Burke RE (2006). Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci USA 103, 18757-18762.
29. Ruderman NB, Kapeller R, White MF, Cantley LC (1990). Activation of phosphatidylinositol 3-kinase by insulin. Proc Natl Acad Sci USA 87, 1411-1415.
30. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
31. Scheid MP, Marignani PA, Woodgett JR (2002). Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 22, 6247-6260.
32. Sturla L, Fresia C, Guida L, Bruzzone S, Scarfi S, Usai C, Fruscione F, Magnone M, Millo E, Basile G, et al. (2009). LANCL2 is necessary for abscisic acid binding and signaling in human granulocytes and in rat insulinoma cells. J Biol Chem 284, 28045-28057.
33. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D (2002). Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 9, 940-944.
34. Yang Q, Inoki K, Ikenoue T, Guan KL (2006). Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20, 2820-2832.
35. Yao Y, Suraokar M, Darnay BG, Hollier BG, Shaiken TE, Asano T, Chen CH, Chang BH, Lu Y, Mills GB, et al. (2013). BSTA promotes mTORC2- mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. Sci Signal 6, ra2.
36. Zhang W, Wang L, Liu Y, Xu J, Zhu G, Cang H, Li X, Bartlam M, Hensley K, Li G, et al. (2009). Structure of human lanthionine synthetase C-like protein 1 and its interaction with Eps8 and glutathione. Genes Dev 23, 1387-1392.